Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bumetanide kinetics in renal failure.

P J Pentikäinen, A Pasternack, E Lampainen

    Clinical Pharmacology and Therapeutics
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.

    Scientific reports·2016
    Same author

    Death rates and causes of death in patients with rheumatoid arthritis: a population-based study.

    Scandinavian journal of rheumatology·2004
    Same author

    Presence of apolipoprotein E epsilon4 allele predisposes to early onset of primary Sjogren's syndrome.

    Rheumatology (Oxford, England)·2004
    Same author

    Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome.

    Rheumatology (Oxford, England)·2004
    Same author

    Urinary matrix metalloproteinase-9 and interleukin-6 and renal manifestations of primary Sjogren's syndrome.

    Rheumatology (Oxford, England)·2004
    Same author

    Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis.

    Nephron. Clinical practice·2004

    Renal failure significantly alters bumetanide kinetics, leading to reduced renal clearance and increased free drug fraction. These changes result in a larger volume of distribution and longer elimination half-life in patients with kidney disease.

    Area of Science:

    • Pharmacokinetics
    • Nephrology
    • Drug Metabolism

    Background:

    • Renal failure impacts drug elimination pathways.
    • Understanding bumetanide's behavior in kidney disease is crucial for safe and effective dosing.

    Purpose of the Study:

    • To investigate the pharmacokinetic changes of bumetanide in patients with varying degrees of renal failure.
    • To compare bumetanide kinetics between healthy individuals and renally impaired patients.

    Main Methods:

    • Administered intravenous 14C-bumetanide to healthy subjects and patients with renal failure.
    • Utilized a two-compartment open model to analyze drug kinetics.
    • Assessed renal clearance, nonrenal clearance, and free fraction of bumetanide.

    Main Results:

    Related Experiment Videos

    • Patients with renal failure exhibited lower renal clearance and a higher free fraction of bumetanide.
    • Elimination half-life and volume of distribution were increased in the renal failure group.
    • Nonrenal clearance increased, while total plasma clearance remained unchanged.

    Conclusions:

    • Reduced renal clearance and increased free bumetanide fraction are key alterations in renal failure.
    • These changes necessitate careful consideration for bumetanide dosing in patients with impaired kidney function.